ASCO GI 2024-话题@MedSci

#ASCO GI 2024#

0篇内容 | 856人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2184127, encodeId=4b15218412eca, content=<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a> <a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a> <a href='/topic/show?id=c6791105e05f' target=_blank style='color:#2F92EE;'>#晚期胆道癌#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024 ：阿替利珠单抗联合化疗与或不联合贝伐单抗治疗晚期胆道癌的疗效比较（IMbrave151研究）, objectType=article, longId=811126, objectId=9047811126cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=9047811126cc, replyNumber=0, likeNumber=110, createdTime=2024-01-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9047811126cc, moduleTitle=ASCO GI 2024 ：阿替利珠单抗联合化疗与或不联合贝伐单抗治疗晚期胆道癌的疗效比较（IMbrave151研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9047811126cc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183986, encodeId=781e21839867a, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=2024 ASCO GI｜胃癌与食管癌亮点研究汇总, objectType=article, longId=810895, objectId=9e6981089526, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=9e6981089526, replyNumber=0, likeNumber=93, createdTime=2024-01-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=9e6981089526, moduleTitle=2024 ASCO GI｜胃癌与食管癌亮点研究汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e6981089526)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183453, encodeId=cc1d218345337, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a> <a href='/topic/show?id=75d25989596' target=_blank style='color:#2F92EE;'>#晚期食管癌#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：一线pembrolizumab+化疗治疗晚期食管癌：3期KEYNOTE-590研究的5年结果 , objectType=article, longId=810642, objectId=005881064236, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=005881064236, replyNumber=0, likeNumber=72, createdTime=2024-01-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=005881064236, moduleTitle=ASCO GI 2024：一线pembrolizumab+化疗治疗晚期食管癌：3期KEYNOTE-590研究的5年结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005881064236)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183456, encodeId=3cd1218345684, content=<a href='/topic/show?id=db0c5989656' target=_blank style='color:#2F92EE;'>#晚期食管鳞癌#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：纳武利尤单抗+化疗和纳武利尤单抗+伊匹木单抗用于晚期食管鳞癌（ESCC）一线治疗的临床疗效（ CheckMate 648研究）, objectType=article, longId=810645, objectId=dac28106454b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=dac28106454b, replyNumber=0, likeNumber=150, createdTime=2024-01-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dac28106454b, moduleTitle=ASCO GI 2024：纳武利尤单抗+化疗和纳武利尤单抗+伊匹木单抗用于晚期食管鳞癌（ESCC）一线治疗的临床疗效（ CheckMate 648研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dac28106454b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183149, encodeId=e76621831490b, content=<a href='/topic/show?id=b860101129ac' target=_blank style='color:#2F92EE;'>#食管鳞状细胞癌#</a> <a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：一线tiragolumab+阿替利珠单抗联合化疗治疗食管鳞状细胞癌（ESCC）患者的疗效（SKYSCRAPER-08研究）, objectType=article, longId=810442, objectId=d392810442ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=d392810442ce, replyNumber=0, likeNumber=88, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d392810442ce, moduleTitle=ASCO GI 2024：一线tiragolumab+阿替利珠单抗联合化疗治疗食管鳞状细胞癌（ESCC）患者的疗效（SKYSCRAPER-08研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d392810442ce)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183153, encodeId=5fdc2183153bb, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a> <a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：pembrolizumab联合FLOT与单纯FLOT作为局部晚期胃癌和胃食管交界处癌的新辅助和辅助治疗：KEYNOTE-585研究3期中期分析, objectType=article, longId=810454, objectId=91158104547c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=91158104547c, replyNumber=0, likeNumber=84, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=91158104547c, moduleTitle=ASCO GI 2024：pembrolizumab联合FLOT与单纯FLOT作为局部晚期胃癌和胃食管交界处癌的新辅助和辅助治疗：KEYNOTE-585研究3期中期分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91158104547c)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

食管鳞状细胞癌 ESCC ASCO GI 2024

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#贝伐单抗# #阿替利珠单抗# #晚期胆道癌# #ASCO GI 2024#

ASCO GI 2024 ：阿替利珠单抗联合化疗与或不联合贝伐单抗治疗晚期胆道癌的疗效比较（IMbrave151研究）

2024-01-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #食管癌# #ASCO GI 2024#

2024 ASCO GI｜胃癌与食管癌亮点研究汇总

2024-01-25发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#Pembrolizumab# #晚期食管癌# #ASCO GI 2024#

ASCO GI 2024：一线pembrolizumab+化疗治疗晚期食管癌：3期KEYNOTE-590研究的5年结果

2024-01-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期食管鳞癌# #纳武利尤单抗# #ASCO GI 2024#

ASCO GI 2024：纳武利尤单抗+化疗和纳武利尤单抗+伊匹木单抗用于晚期食管鳞癌（ESCC）一线治疗的临床疗效（ CheckMate 648研究）

2024-01-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#食管鳞状细胞癌# #ESCC# #ASCO GI 2024#

ASCO GI 2024：一线tiragolumab+阿替利珠单抗联合化疗治疗食管鳞状细胞癌（ESCC）患者的疗效（SKYSCRAPER-08研究）

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期胃癌# #Pembrolizumab# #ASCO GI 2024#

ASCO GI 2024：pembrolizumab联合FLOT与单纯FLOT作为局部晚期胃癌和胃食管交界处癌的新辅助和辅助治疗：KEYNOTE-585研究3期中期分析

2024-01-22发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务